Early, prolonged and late grade 3-4 cytopenias following CAR T-cell therapy as reported in registry studies and real-world data
| . | Early (<30 d from infusion) . | Prolonged (30-90 d from infusion) . | Late (>90 d from infusion) . |
|---|---|---|---|
| CD19-directed CAR T-cells, pediatrics | |||
| ELIANA12 | Neutropenia: 53% | Neutropenia: 34% | |
| Thrombocytopenia: 41% | Thrombocytopenia: 27% | ||
| CD19-directed CAR T-cells, adults | |||
| ZUMA-113,14 | Neutropenia: 78% | Neutropenia: 11% | |
| Thrombocytopenia: 38% | Thrombocytopenia: 7% | ||
| Anemia: 43% | Anemia: 3% | ||
| JULIET15 | Neutropenia: 33% | Neutropenia: 24% | Grade 3-4 neutropenia: 0% |
| Thrombocytopenia: 28% | Thrombocytopenia: 41% | Thrombocytopenia: 38% | |
| Anemia: 39% | |||
| TRANSCEND16 | Neutropenia: 60% | Neutropenia: 7% | |
| Thrombocytopenia: 27% | Thrombocytopenia: 22% | ||
| Anemia: 37% | Anemia: 2% | ||
| ZUMA-217 | Neutropenia: 85% | Neutropenia: 16% | |
| Thrombocytopenia: 51% | Thrombocytopenia:16% | ||
| Anemia: 50% | Anemia: 12% | ||
| ZUMA-318 | Neutropenia: 27% | Neutropenia: 25% | |
| Thrombocytopenia: 30% | Thrombocytopenia: 18% | ||
| Anemia: 49% | Anemia: 7% | ||
| ZUMA-519 | Neutropenia: 33% | ||
| Thrombocytopenia: 15% | |||
| Anemia: 25% | |||
| BCMA-directed CAR T-cells, adults | |||
| KarMMa20 | Neutropenia: 89% | Neutropenia: 41% | |
| Thrombocytopenia: 52% | Thrombocytopenia: 48% | ||
| Anemia: 60% | |||
| CARTITUDE-121 | Neutropenia: 95% | Neutropenia: 29% | |
| Thrombocytopenia: 60% | Thrombocytopenia: 27% | ||
| Anemia: 68% | Anemia: 27% | ||
| Real-world studies | |||
| Jain et al4 | Neutropenia: 67% | Neutropenia: 20% | Neutropenia: 5% |
| Thrombocytopenia: 49% | Thrombocytopenia: 10% | Thrombocytopenia: 0% | |
| Anemia: 39% | Anemia: 7% | Anemia: 0% | |
| Juluri et al5 | Neutropenia: 46% | ||
| Thrombocytopenia: 34% | |||
| Anemia: 15% | |||
| Logue et al6 | Neutropenia: 39% | Neutropenia: 11% | |
| Thrombocytopenia: 51% | Thrombocytopenia: 28% | ||
| Anemia: 29% | Anemia: 15% |
| . | Early (<30 d from infusion) . | Prolonged (30-90 d from infusion) . | Late (>90 d from infusion) . |
|---|---|---|---|
| CD19-directed CAR T-cells, pediatrics | |||
| ELIANA12 | Neutropenia: 53% | Neutropenia: 34% | |
| Thrombocytopenia: 41% | Thrombocytopenia: 27% | ||
| CD19-directed CAR T-cells, adults | |||
| ZUMA-113,14 | Neutropenia: 78% | Neutropenia: 11% | |
| Thrombocytopenia: 38% | Thrombocytopenia: 7% | ||
| Anemia: 43% | Anemia: 3% | ||
| JULIET15 | Neutropenia: 33% | Neutropenia: 24% | Grade 3-4 neutropenia: 0% |
| Thrombocytopenia: 28% | Thrombocytopenia: 41% | Thrombocytopenia: 38% | |
| Anemia: 39% | |||
| TRANSCEND16 | Neutropenia: 60% | Neutropenia: 7% | |
| Thrombocytopenia: 27% | Thrombocytopenia: 22% | ||
| Anemia: 37% | Anemia: 2% | ||
| ZUMA-217 | Neutropenia: 85% | Neutropenia: 16% | |
| Thrombocytopenia: 51% | Thrombocytopenia:16% | ||
| Anemia: 50% | Anemia: 12% | ||
| ZUMA-318 | Neutropenia: 27% | Neutropenia: 25% | |
| Thrombocytopenia: 30% | Thrombocytopenia: 18% | ||
| Anemia: 49% | Anemia: 7% | ||
| ZUMA-519 | Neutropenia: 33% | ||
| Thrombocytopenia: 15% | |||
| Anemia: 25% | |||
| BCMA-directed CAR T-cells, adults | |||
| KarMMa20 | Neutropenia: 89% | Neutropenia: 41% | |
| Thrombocytopenia: 52% | Thrombocytopenia: 48% | ||
| Anemia: 60% | |||
| CARTITUDE-121 | Neutropenia: 95% | Neutropenia: 29% | |
| Thrombocytopenia: 60% | Thrombocytopenia: 27% | ||
| Anemia: 68% | Anemia: 27% | ||
| Real-world studies | |||
| Jain et al4 | Neutropenia: 67% | Neutropenia: 20% | Neutropenia: 5% |
| Thrombocytopenia: 49% | Thrombocytopenia: 10% | Thrombocytopenia: 0% | |
| Anemia: 39% | Anemia: 7% | Anemia: 0% | |
| Juluri et al5 | Neutropenia: 46% | ||
| Thrombocytopenia: 34% | |||
| Anemia: 15% | |||
| Logue et al6 | Neutropenia: 39% | Neutropenia: 11% | |
| Thrombocytopenia: 51% | Thrombocytopenia: 28% | ||
| Anemia: 29% | Anemia: 15% |